GlassScriptPhysician profile
Alexandra Rogerson
NPI 1851918320
$1,385.91
in general payments reported to CMS, 2019-2025
10 companies · $14.58 in 2025
The $14.58 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.94 · 2022: $1,028 · 2023: $228 · 2024: $14.68 · 2025: $14.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.55 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.04 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $233.67 | 2022-2023 | |
| Inspire Medical Systems, INC. | $163.67 | 2022 | |
| Neurocrine Biosciences, INC. | $162.43 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $134.15 | 2022 | |
| Lundbeck LLC | $124.92 | 2022 | |
| Amgen INC. | $116.76 | 2022 | |
| Novo Nordisk INC | $113.22 | 2023 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $30.79 | 2023 | |
| Glaxosmithkline, LLC. | $29.26 | 2024-2025 | Shingrix, Bexsero, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Rogerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.